Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory
Lucy Batizovsky | March 25, 2026 | News story | Research and Development | AI, NVIDIA, Roche
Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance graphics processing units (GPUs) across the US and Europe and making it the largest announced hybrid-cloud AI factory.
Designed to accelerate the development of diagnostics solutions and therapeutics, Roche’s combined on-premise and cloud GPU infrastructure now exceeds 3,500 Blackwell GPUs.
Roche started a strategic collaboration with NVIDIA in 2023, combining Roche’s scientific expertise with NVIDIA AI infrastructure to speed up drug development.
Wafaa Mamilli, Roche’s Chief Digital and Technology Officer, said: “Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain – from discovery to development, manufacturing and commercialisation – transforming how we deliver the next generation of medicines and diagnostics solutions.”
A high-performance supercomputing platform, Roche’s AI factory powers digital transformation across multiple parts of the organisation, including R&D, manufacturing, diagnostics, digital pathology and digital health.
In digital health, NVIDIA NeMo Guardrails are used to ensure safe and reliable conversational AI for healthcare.
Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development (gRED), said: “Our expanded collaboration with NVIDIA and the launch of this AI factory further strengthens our leadership in AI-driven drug discovery and development.
“By providing the massive computational power needed to continue to scale our Lab-in-the-Loop strategy – a space we have pioneered for over five years – our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine.”
Related Content
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
Liverpool launches £20m lab for infectious disease drug discovery
A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
